Trial Profile
Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 27 Nov 2023 Results (n=61) assessing the efficacy and safety of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer, published in the Cancer.
- 02 Nov 2023 Planned number of patients changed from 175 to 120.
- 02 Nov 2023 Planned End Date changed from 15 Dec 2023 to 15 Dec 2024.